Cost Effectiveness of Treatment Sequences in Advanced Renal Cell Carcinoma-Reference-Cited by-同舟云学术

Cost Effectiveness of Treatment Sequences in Advanced Renal Cell Carcinoma

Published:2023-06 Issue:3 Volume:6 Page:331-338
ISSN:2588-9311
Container-title:European Urology Oncology
language:en
Short-container-title:European Urology Oncology

Author:

Mason Neil T.,Joshi Vidhu B.,Adashek Jacob J.,Kim Youngchul,Shah Savan S.,Schneider Amy M.,Chadha Juskaran,Jim Heather S.L.,Byrne Margaret M.,Gilbert Scott M.,Manley Brandon J.,Spiess Philippe E.,Chahoud Jad

Publisher

Elsevier BV

Subject

Urology,Radiology, Nuclear Medicine and imaging,Oncology,Surgery

Reference39 articles.

1. Lenvatinib plus pembrolizumab or everolimus for advanced renal cell carcinoma;Motzer;N Engl J Med,2021

2. Nivolumab plus cabozantinib versus sunitinib for advanced renal-cell carcinoma;Choueiri;N Engl J Med,2021

3. Avelumab plus axitinib versus sunitinib for advanced renal-cell carcinoma;Motzer;N Engl J Med,2019

4. Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 4-year follow-up of the phase III CheckMate 214 trial;Albiges;ESMO Open,2020

5. Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426): extended follow-up from a randomised, open-label, phase 3 trial;Powles;Lancet Oncol,2020

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Scoping review of economic analyses of rare kidney diseases;Kidney International Reports;2024-09

2. Feasibility of a Smartphone Application for Education and Symptom Management of Patients With Renal Cell Carcinoma on Combined Tyrosine Kinase and Immune Checkpoint Inhibitors;JCO Clinical Cancer Informatics;2024-07

3. Cost-utility of Initial Management of High-grade T1 Bladder Cancer With Intravesical BCG vs Immediate Radical Cystectomy;Urology;2024-05

4. Cost-effectiveness of Nivolumab Plus Cabozantinib Versus Cabozantinib as First-Line Treatment of Metastatic Renal Cell Carcinoma;Clinical Genitourinary Cancer;2023-12